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ABSTRACT  
 
Cisplatin is a chemotherapeutic agent with varying side effects. Berberine compounds in 
Tinospora crispa and ursolic acids in Hedyotis corymbosa L are known to have high cytotoxic 
activities. This study was aimed to examine the effects of the combination of cisplatin, the 
ethanolic extract of Hedyotis corymbosa L.(EEHC), and the ethanolic extract of Tinospora crispa 
roots (EETC) on enhanced breast cancer cell sensitivity by apoptotic induction and cell cycle 
modulation. Cytotoxic effects were tested using the MTT assay in breast cancer cells, 4T1. The 
combination test of cisplatin and the extracts yielded combination index (CI) and cell viability, and 
its effects on the induction of apoptosis and cell cycle modulation were observed by the flow 
cytometry method. The results of the cytotoxic test showed CI of less than one for 1 mg/mL EEHC, 
6 mg/mL EETC, and 1.68 mg/mL cisplatin. The EEHC-EETC-cisplatin combination accumulated 
cells in the S phase (29.98%) and induced apoptosis in 4T1 cells. It proves that EEHC and EETC 
can be developed as co-agents with cisplatin to improve the effectiveness of breast cancer 
chemotherapeutic treatment. 
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INTRODUCTION  
Cancer is one of the leading causes of death in the world. In 2008, it reportedly led to 
approximately 7.6 million deaths (around 13% of total mortality), and this figure is expected to 
increase to 13.1 million in 2030 (WHO, 2013). Breast cancer ranks first in the number of cases of 
cancer in women worldwide, with the incidence rate of 1,676,633 (IARC, 2012). 
Chemotherapy is the widely proposed treatment for cancer. Chemotherapeutic agents 
generally have low selectivity because they are antiproliferative against cancer cells and healthy 
cells (Valeriote et al., 2002). Also, several chemotherapeutic agents have a narrow therapeutic 
index and can lead to multiple drug resistance and adverse side effects (Minami et al., 2010). 
Chemotherapy drugs that are mostly used in the treatment of breast cancer are cisplatin. Cisplatin, 
especially in high doses, can cause varying side effects (Florea and Busselberg, 2011), including 
neurotoxicity, nephrotoxicity (Milosavlievic et al., 2010), and bone marrow suppression. 
Therefore, research focusing on finding active and selective methods to cure breast cancer becomes 
necessary. 
Cancer cell treatment strategy is not a one-target but multiple-target mechanism, especially 
for cell proliferation and migration (Kemper et al., 2014). 4T1 is an example of cancer cells in the 
metastatic phase that show migration and invasion (Kaur et al., 2012). 
Indonesia has various resources that can be potentially developed into chemotherapeutic 
agents against breast cancer, such as Hedyotis corymbosa L. and Tinospora crispa. H. corymbosa 
contains ursolic acid, which is known to possess antiproliferative and antiangiogenetic activities, 
preventing the spread of cancer cells to other organs. Also, ursolic acid can inhibit the regulation of 
proinflammatory cytokines expression by inhibiting the activation of NF-κB (Foo and Nolan, 
1999). Berberine isolated from Tinospora crispa has cytotoxic activity against HCT-8 cells, NUGC 
Cells, and Hone-1 cells (Damu et al., 2009). 
Doses of chemotherapeutic agents can be reduced by combining them with compounds 
found in natural ingredients as an attempt to minimize adverse side effects while maintaining 
similar therapeutic properties against target cells (Zhao et al., 2005). Moreover, Zhao et al. (2005) 
confirm that H. corymbosa and T. crispa extracts can be potentially developed in combination 
therapy with cisplatin for breast cancer treatment. This combination is expected to lower the 
required dose of cisplatin and, consequently, lessen its side effects. This study was conducted to 
assess the cytotoxic effects of the combination of the ethanolic extract of H. corymbosa (EEHC), 
the ethanolic extract of T. crispa (EETC), and cisplatin through cell cycle modulation and apoptosis 
induction. 
 
MATERIALS AND METHOD  
Materials 
Materials used in this research were Hedyotis corymbosa L. and Tinospora crispa powder 
obtained from UPT Materi Materia Medica Batu, Malang.  
 
Methods 
Extraction of H. corymbosa roots and T. crispa leaves 
H. corymbosa weighing 250 grams was macerated with 1 liter of 96% ethanol for one day. 
The liquid was then evaporated with a solvent to create a thick consistency (Rollando, 2018). This 
procedure was also applied to T. crispa. 
 
 Identification of chemical compounds in extracts 
Two mg of both extracts were dissolved in 1 mL of ethanol. The extracts were spotted on 
TLC plates and then inserted into a chamber containing chloroform-ethanol 9: 1 as the mobile 
phase. Once the mobile phase reached the predefined mark, the plates were removed, sprayed with 
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Cerium (IV) Sulfate hydrate and Dragendorff's reagent, and dried in an oven. The band formed was 
then observed to calculate the HRF value.  
 
 Cell preparation and harvesting 
The 4T1 cells were transferred to a conical tube containing high-glucose DMEM and 
centrifuged at 600 rpm for 5 minutes. After the supernatant was discarded, new media was added to 
the flask, and the cells were suspended until homogeneous. Cell suspensions were grown in Tissue 
Culture Dish (TCD) and incubated in a CO2 incubator at 37°C. Cells were observed under a 
microscope and incubated in a 5% CO2 incubator. After reaching ±80% confluence, they were 
harvested by removing the media. Then, the cells were washed with 3 mL of PBS 2 times, added 
with 0.25% trypsin-EDTA, and incubated for 1 minute in a CO2 incubator.  
A total of 3 mL of the media were added into TCD that contained the cells. Then, the cells 
were resuspended on the walls and at the bottom of TCD using a micropipette to prevent cell 
clumping. The cell suspension was transferred to a new sterile conical tube, and it was enumerated 
using a hemocytometer and cell counter. The cells were then formed into a cell suspension at 
predefined concentrations. The cytotoxic tests of single and combination solutions were performed 
at a density of 8x10
4
 cells. 
A stock solution of each extract was diluted with the culture medium to obtain 
concentrations of 1, 10, 25, 50, 75, 100, and 200 mg/mL. These solutions were used in single 
cytotoxic tests. Meanwhile, the cisplatin test solution was diluted with the culture medium at 
concentrations of 0.5, 1, 2, 4, and 8 µg/mL (Rollando, 2018). 
 
Cytotoxic tests of single and combination treatments using MTT assay 
Cells were harvested, diluted with the culture medium, implanted into a 96-well microplate 
(with a volume of 100 mL/wells), and incubated for 24 hours in a 5% CO2 incubator. Before the 
treatment, the media in the plate was removed and washed with 1x PBS (as many as 100 
mL/pitting). Afterward, the PBS was removed, and the cells were given a test solution of 100 
mL/pitting (Rollando, 2018). 
After 24 hours of incubation, the cells were washed with PBS, added with 100 mL/pitting of 
MTT reagent, and incubated for 3-4 hours at 37°C. The stopper solution (10% SDS in 0.01 N HCl) 
was added, with a volume of 100 mL/wells. The cells were incubated overnight in the dark at room 
temperature and then measured with an ELISA reader at λ 595 nm to obtain absorption equivalent 
to the absorbance of living 4T1 cells (Rollando, 2018). 
The absorbance data of the single treatment were converted into percent viability, which is a 
factor in the calculation of IC50. Based on the IC50 value, the cytotoxicity of the EEHC-EETC-
cisplatin combination at various levels was tested. The results are shown in Table I. 
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 Flow cytometry  
Cells (5 x 10
5
cells/wells) were grown in a 6-well plate, incubated for 24 hours, and treated 
with EEHC, EETC, cisplatin (WAKO), and their combination. For the cell cycle analysis, 
trypsinized adherent cells were collected and detected by adding the flow cytometry reagent 
(PI+RNase+Triton-X) and then incubated for 10 minutes. The apoptotic cells were detected using 
the FLOUS-Annexin V Apoptosis Detection Kit. The cell suspension was transferred into a flow 
cytometer tube, and cell cycle profiles were read by FACSCalibur flow cytometer. The Data were 
analyzed in the Flowing software to determine the distribution of cells in each phase of the cell 
cycle (Rollando, 2018). 
 
Data Analysis 
Analysis of single cytotoxic agents 
 
Data on absorbance were converted to percent viability using the formula below: 
 
 
Cell viability was analyzed in Microsoft Excel 2007 to obtain linearity (r) and IC50 from the 
curve of concentrations (log values) and the percentage of cell viability. The r-value was compared 
with the table (p <0.05). The effectiveness of the test compound was determined by the percentage 
of reduction in cell viability (Rollando, 2018). 
 
Comparative analysis of cell viabilities in the EEHC-EETC-Cisplatin combination treatment 
The cytotoxic effects of the mixture were conducted by MTT assay. The combined effects 
were identified by calculating the Chou’s Combination Index and Drug Reduction Index (DRI) 
(Reynolds and Maurer, 2005) for EEHC, EETC, and cisplatin in CompuSyn program. 
 
 
 
 
 
Table I. Comparison of  concentrations in the  combination of  Hedyotis corymbosa L. Extract, 
Tinospora crispa Extract, and Cisplatin 
Comparison of Treatment 
Combinations 
Single treatment Single treatment Single treatment 
EEHC (IC50 1/12); 
 EETC (1/12 IC50);  
C (1/12 IC50) 
EEHC (1/12 IC50) EETC (1/12 IC50) C (1/12 IC50) 
EEHC (1/6 IC50);  
EETC (1/6 IC50);  
C (1/6 IC50) 
EEHC (1/6 IC50); EETC (1/6 IC50) C (1/6 IC50) 
EEHC (1/3 IC50); 
 EETC (1/3 IC50);  
C (1/3 IC50) 
EEHC (1/3 IC50) EETC (1/3 IC50) C (1/3 IC50) 
KS KS KM KM 
Description: EEHC = the ethanolic extract of Hedyotis corymbosa L.; EETC = the ethanolic extract 
of Tinospora crispa roots; C = Cisplatin; KS = Control Cells; KM = Control Media 
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Description: (Dx) 1, (Dx) 2, and (Dx) 3 denote the concentration of single compounds for combination 
treatment (x). (D)1, (D)2, and (D)3 denote the concentration of each test compound used to examine the 
combination. 
 
Table II. Combination index (CI) interpretation (Matthews et al., 2017) 
 
 
 
 
 
 
 
 
 
 
 
Apoptosis and cell cycle analyses 
The data on flow cytometry show the percentage of cells in four quadrants, namely LL 
(lower left, representing the percentage of live cells), LR (lower right, the percentage of early 
apoptotic cells), UL (upper left, the percentage of necrotic cells), and UR (upper right, the 
percentage of late apoptotic cells). These data were analyzed to identify the distribution of cells in 
each phase of the cell cycle (i.e., G1, S, and G2/M). The inhibition of the cell cycle can be detected 
by comparing the therapeutic effects of the test solution on control cells. 
 
RESULTS AND DISCUSSION  
Chemical compounds of the test extracts  
The chemical examination was carried out to confirm that  EETC and EEHC contain 
alkaloids and terpenoids, which have been scientifically proven to exhibit cytotoxic activity (Lin et 
al., 2002). The results of the identification test using Cerium (IV) Sulfate hydrate as the reagent 
showed that the EETC had an HRF of 5, while EEHC had HRF values of 16 and 25 (Figure 1). 
 
Figure 1. Test results with the Dragendorff’s reagent for (a) EEHC and (c) EETC. Test 
results with Cerium (IV) Sulfate for (b) EETC and (d) EEHC. Elution was carried 
out with silica gel 60 F254 as the stationary phase and the mixture of chloroform: 
methanol (9: 1) as the mobile phase. The detection was carried out using visible light 
 
CI values Interpretations 
<0.1 Powerful synergistic effect 
0.1-0.3 Strong synergistic effect 
0.3-0.7 Synergistic effect 
0.7-0.9 Mild-moderate synergistic effect 
0.9-1.1 Nearly addictive effect 
1.1-1.45 Mild-moderate antagonistic effect 
1.45-3.3 Antagonistic effect 
> 3.3 Strong-very strong antagonistic effect 
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The above results indicate that the plant extracts are both carbon atoms (Harborne, 1987). 
When the EETC plate was sprayed with the Dragendorff’s reagent, a reddish-orange stain with an 
HRF of 25 appeared. On the contrary, there was no stain formed on the EEHC plate. In this case, 
orange-brown stains represent a positive reaction for alkaloids (MOH, 1985). Accordingly, EETC 
contains alkaloids, whereas EEHC does not. Other compounds found in both extracts are one type 
of triterpenoid in EETC (Aprianto et al., 2017) and two triterpenoids in EEHC, namely, 
cycloeucalenol and cycloeucalenone (Waqas et al., 2016). 
 
Single cytotoxic activity test results of EEHC, EETC, and cisplatin against 4T1 Cells  
Cytotoxic tests were designed to determine the potential of EEHC, EETC, and cisplatin in 
inhibiting breast cancer cells, 4T1. The parameter observed was IC50, i.e., the concentration at 
which a substance triggers the cellular death of 50% of the population. 
 
Table III. IC50 values of EEHC, EETC, and cisplatin in 4T1 Cells 
Samples IC50 
EEHC 5.98 ± 1.26 mg/mL 
EETC 14.35 ± 0.54 pg/mL 
Cisplatin 5.04 ± 0.75 mg/mL 
 
Treatments with EEHC (Figure 2b), EETC (Figure 2c), and cisplatin (Figure 2d) showed a 
more significant decrease in the live-cell population compared to controls (Figure 2a). The cell size 
shrank due to due to the loss of cytoplasmic fluid—i.e., the result of membrane disruption, as 
shown by the detached cell after the above treatments (Florea and Busselberg, 2011). 
 
  
A B 
 
 
C D 
Figure 2. The Effects of Various Treatments on 4T1 Cells. A total of 8000 cells/wells in 96-
well plates after 24 hours of incubation in high-glucose DMEM media. 
Observations were carried out under an inverted microscope with 100x 
magnification. (A) Control cells; (B) 5.98 pg/mL EEHC; (C) 14.35 ug/mL EETC, 
(D) 5.04 ug/mL Cisplatin 
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Cytotoxic activity test results of the EEHC-EETC-cisplatin combination against 4T1 Cells 
This study used a series of concentrations for each test substance, namely, 0.5, 1, and 2 
mg/mL EEHC, 2.5, 5, and 10 mg/mL EETC, and 1.25, 2.5, and 5 µL cisplatin. The combination of 
EEHC, EETC, and cisplatin required to produce the given effects (i.e., 1/12, 1/6, and 1/3 IC50) 
produced CI of <1 (Table 4). In other terms, this combination has a synergistic effect.  
 
Table IV. The combination index (CI) values of cisplatin-EETC-EEHC for 4T1 cells 
Concentration 
ratio 
Cell viability 
(%) 
CI 
1/12 IC50 52.86 0.43 
1/6 IC50 45.76 0.58 
1/3 IC50 39.87 0.86 
 
Modulation of 4T1 cell cycle in the EEHC-EETC-cisplatin combination treatment 
DNA synthesis in cancer cells through the cell cycle is similar to that of healthy cells (Foster, 
2008). One of the main targets in inhibiting the proliferation of cancer cells in the modulation of 
the cell cycle is observable by flow cytometry (King, 2000). Flow cytometry can detect each phase 
of the cell cycle based on the number of chromosomes in each phase (i.e., G1, S, and G2/M) (Foster, 
2008). Propidium iodide was used to color the cells in each phase (Ross et al., 2003). The cell cycle 
profile was observed at the 24th hour (King, 2000). The percentage distribution of the cell cycle is 
presented in detail in Table V. 
 
Table V. The Distribution of Cell Cycle (in percent) 
Samples G1 (%) S (%) G2 / M (%) % CV 
Control 48.98 11.62 24.68 8.87 
A (1 ug/ml EEHC) 42.82 17.92 16.83 9.81 
B (6 ug/ml EETC) 34.83 13.82 24.83 8.98 
C (1.68 µM Cisplatin) 43.87 11.24 29.93 9.81 
The combination of A, B, and C 24.82 29.98 15.98 7.87 
 
The test results showed that single treatments with EEHC, as well as cisplatin, caused 
accumulation in S phase, whereas EETC caused accumulation in S and G2/M phases. Meanwhile, 
when compared to the control cells, the combination of EEHC, EETC, and cisplatin caused a 
collection of cells in the S phase. In the combination treatment, the percentage distribution of the S 
phase was 29.98% or higher than single treatments with cisplatin, which amounted to 11.24%. The 
combination treatment result increased on the S phase (29.98 %), and the cells accumulate in S 
phase due to cell cycle arrest in this phase. 
 
Observation of apoptosis in the EEHC-EETC-cisplatin combination treatment 
Induced apoptosis was used to understand the mechanism of 4T1 cell death caused by 
EEHC, EETC, cisplatin, and their combinations after 24 hours of incubation. Apoptosis was 
observed from the EEHC-EETC-Cisplatin combination at 1/6 IC50 concentration. Annexin V is a 
member of the family of phospholipid-binding protein on negatively charged cell membranes. Cell 
death caused by apoptosis or necrosis can be distinguished by staining propidium iodide (PI) 
through intercalation with DNA (Zhang et al., 1997).  
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Table VI. The percentage of 4T1 cell mortality after treatment 
 
After single and combination treatments (Table VI), the cell death of the control cell is at a 
rate of 3.94%. Single treatments using EEHC, EETC, and cisplatin caused, respectively, 3.61%, 
4.63%, and 6.04% of cell death, whereas their combination resulted in 13.78% of cell death. These 
results prove that compared to the single use of cisplatin, the combination treatment can increase 
cell death by 7.4%. The extract can inhibit the phosphorylation of signal transducers and activate 
STAT, which is a prerequisite for the transcription process (Rabbi et al., 2008). 
 At the molecular level, c-Myc decrease transcription, mitochondrial biogenesis, the 
biosynthesis of RNA and proteins, anaplerosis, and glutaminolysis and increase gene inhibitors. 
Meanwhile, at the cellular level, they reduce cell proliferation, transformation metabolism, and the 
capacity of metastasis (Miller et al., 2012). 
 
CONCLUSION 
The optimum combination of the ethanolic extract of Hedyotis corymbosa L. (1/6 IC50, 
1μg/mL), the ethanolic extract of Tinospora crispa (1/6 IC50, 6μg/mL), and cisplatin (1.68 mg/mL) 
can enhance the cytotoxic effects of cisplatin against breast cancer cells, chiefly 4T1. It has a 
synergistic effect with CI of 0.58, induces S-phase cell cycle arrest in 4T1 cells, and increases the 
induction of apoptosis in these cells. 
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